AbbVie has granted Pfizer a non-exclusive global licence to its Humira IP, as announced on Friday, November 30.
Proposed amendments to the EU’s supplementary protection certificate manufacturing waiver risk “further disincentivising investment” in Europe, according to the European Federation of Pharmaceutical Industries and Associations.
The National Health Service England is set to make record-breaking savings after negotiating deals with five manufacturers of low-cost biosimilar versions of the NHS's most expensive drug.
Japan-based Takeda Pharmaceutical has persuaded the European Union Intellectual Property Office that an applied-for trademark would be confused with its own earlier-registered mark
The EU General Court dismissed Canada-based Endoceutics’ trademark appeal in a win for medical technology company Merck KGaA on Thursday, November 22.
Denmark-based Leo Pharma and Californian rare disease company PellePharm have partnered to develop and commercialise therapies for rare forms of skin cancer.
The EU General Court has upheld a decision to deny Japanese medical device producer Asahi Intecc a trademark for a line of catheters it produces.
The strategies of generic makers in Russia have changed dramatically over the past few years, according to Natalia Gulyaeva, partner at Hogan Lovells.
The EU General Court handed a victory to Merck KGaA late last week, after rejecting a Swiss company’s trademark appeal.
While the pharmaceutical industry has welcomed the draft Withdrawal Agreement for the UK’s departure from the EU, more clarity is still needed, lawyers have told LSIPR.